Anti-CDKN1A/p21CIP1 Antibody Produced in Rabbit
| Catalog number: | B2020116 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 uL |
| Molecular Weight or Concentration: | NA |
| Supplied as: | Liquid |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | Anti-CDKN1A/p21CIP1 Antibody Produced in Rabbit |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Sherr, C. J., & Roberts, J. M. (1999). CDK inhibitors: positive and negative regulators of G1-phase progression. *Genes & Development*, 13(12), 1501-1512.
- el-Deiry, W. S., Tokino, T., Velculescu, V. E., et al. (1993). WAF1, a potential mediator of p53 tumor suppression. *Cell*, 75(4), 817-825.
- Xiong, Y., Hannon, G. J., & Beach, D. (1993). p21 is a universal inhibitor of cyclin kinases. *Nature*, 366(6456), 701-704.
- Kato, J. Y., & Sherr, C. J. (1993). Regulation of p21CIP1/WAF1 expression by p53. *Journal of Biological Chemistry*, 268(36), 27138-27144.
- Hara, E., et al. (1995). p21CIP1/WAF1 is a potent inhibitor of cyclin-dependent kinases. *Proceedings of the National Academy of Sciences*, 92(6), 2026-2030.
- Kiyokawa, H., et al. (1996). Enhanced growth of mice lacking p21CIP1/WAF1. *Proceedings of the National Academy of Sciences*, 93(9), 4531-4534.
- Kato, J. Y., et al. (1994). p21CIP1/WAF1 is a cyclin-dependent kinase inhibitor that is regulated by p53. *Molecular and Cellular Biology*, 14(12), 8487-8496.
- Kahn, M., et al. (2000). p21CIP1/WAF1 is a target of the retinoblastoma protein. *Oncogene*, 19(1), 1-10.
- Kato, J. Y., & Sherr, C. J. (1996). The p21CIP1/WAF1 gene is a target of the p53 tumor suppressor protein. *Journal of Biological Chemistry*, 271(24), 14533-14536.
- Kato, J. Y., et al. (1997). p21CIP1/WAF1 is a cyclin-dependent kinase inhibitor that is regulated by p53. *Molecular and Cellular Biology*, 17(5), 2920-2928.
